Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.820
+0.040 (1.44%)
Oct 14, 2025, 12:47 PM EDT - Market open
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Akebia Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $6.90, which forecasts a 144.68% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $8.00.
Price Target: $6.90 (+144.68%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 4, 2025.
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +183.69% | Jun 4, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $7 | Buy | Initiates | $7 | +148.23% | Apr 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +165.96% | Apr 4, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +112.77% | Apr 1, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +112.77% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
230.52M
from 160.18M
Increased by 43.91%
Revenue Next Year
304.49M
from 230.52M
Increased by 32.09%
EPS This Year
-0.02
from -0.33
EPS Next Year
0.10
from -0.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 274.8M | 416.1M | |||
| Avg | 230.5M | 304.5M | |||
| Low | 200.1M | 223.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.6% | 80.5% | |||
| Avg | 43.9% | 32.1% | |||
| Low | 24.9% | -3.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.18 | 0.43 | |||
| Avg | -0.02 | 0.10 | |||
| Low | -0.12 | -0.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.